Riboscience’s first-in-class ENPP1 inhibitor can potentially deliver broad-spectrum anti-cancer immunity.
PROBLEM:
Many cancer treatments result in severe side effects or require lengthy infusions that are difficult for patients to manage.
SOLUTION:
Our clinical compound can be administered orally and is extremely well tolerated across a broad spectrum of cancer patients—allowing patients to avoid lengthy infusions and undesirable effects.
PROBLEM:
Many common tumors are immune-evasive, so they are non-responsive to current immunotherapies.
SOLUTION:
Riboscience’s clinical compound shows efficacy across a range of solid tumors with excellent safety and tolerability.